(WASHINGTON, D.C.) — A third COVID-19 vaccine may soon be on the way, says the Food and Drug Administration.  The FDA agreed Wednesday that Johnson & Johnson meets the requirements for the emergency use authorization review process.

Unlike Moderna and Pfizer’s vaccine, Johnson & Johnson offers a single dose vaccine that does not require intense refrigeration.  However, the vaccine does have a lower efficacy rating than Pfizer and Moderna’s — but is more effective at preventing serious side effects, hospitalizations and death.  

Johnson & Johnson’s vaccine is 66 percent effective at preventing COVID-19 cases with any symptoms and is 85 percent effective at preventing severe illness.

In addition, the company states their vaccine is effective against all variants — but does have less efficacy against the South African variant.

J&J also insists its vaccine helps prevent asymptomatic infections, as well.

Should FDA grant J&J emergency authorization, the company will have four million doses immediately available and, by March, 20 million doses and 100 million doses by the end of June.

As of Thursday, COVID-19 has infected 28.3 million Americans and has killed close to 506,000 people in the U.S., reports Johns Hopkins University.